Overview

Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients

Status:
RECRUITING

Trial end date:
2028-07-01

Target enrollment:

Participant gender:

Summary

The trial aims to evaluate the efficacy of single agent L19IL2, single agent L19TNF, and combination L19IL2+L19TNF given concurrently with anti-PD1 therapy compared to historical control of anti-PD-1 re-challenge alone for anti-PD1 refractory unresectable stage III-IV melanoma.

Phase:

PHASE2

Details

Lead Sponsor:

Philogen S.p.A.

Collaborator:

Merck Sharp & Dohme LLC

Treatments:

daromun
pembrolizumab